PortalPublikationenDual Pathway Inhibition with Low-Dose Direct Factor Xa Inhib...

Dual Pathway Inhibition with Low-Dose Direct Factor Xa Inhibition after Acute Coronary Syndromes-Why Is It Not Used in Clinical Practice?

Standard

Dual Pathway Inhibition with Low-Dose Direct Factor Xa Inhibition after Acute Coronary Syndromes-Why Is It Not Used in Clinical Practice? / Zeymer, Uwe; Schrage, Benedikt; Westermann, Dirk.

in: THROMB HAEMOSTASIS, Jahrgang 118, Nr. 9, 09.2018, S. 1528-1534.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Zeymer, U, Schrage, B & Westermann, D 2018, 'Dual Pathway Inhibition with Low-Dose Direct Factor Xa Inhibition after Acute Coronary Syndromes-Why Is It Not Used in Clinical Practice?', THROMB HAEMOSTASIS, Jg. 118, Nr. 9, S. 1528-1534. https://doi.org/10.1055/s-0038-1668133

APA

Zeymer, U., Schrage, B., & Westermann, D. (2018). Dual Pathway Inhibition with Low-Dose Direct Factor Xa Inhibition after Acute Coronary Syndromes-Why Is It Not Used in Clinical Practice? THROMB HAEMOSTASIS, 118(9), 1528-1534. https://doi.org/10.1055/s-0038-1668133

Vancouver

Zeymer U, Schrage B, Westermann D. Dual Pathway Inhibition with Low-Dose Direct Factor Xa Inhibition after Acute Coronary Syndromes-Why Is It Not Used in Clinical Practice? THROMB HAEMOSTASIS. 2018 Sep;118(9):1528-1534. https://doi.org/10.1055/s-0038-1668133

Bibtex

@article{c1972e029e924d0c8e452a042ea70ae7,
title = "Dual Pathway Inhibition with Low-Dose Direct Factor Xa Inhibition after Acute Coronary Syndromes-Why Is It Not Used in Clinical Practice?",
abstract = "The optimal anti-thrombotic therapy for secondary prevention after an acute coronary syndrome is still a matter of debate. While current guidelines recommend dual anti-platelet therapy with aspirin and a P2Y12 inhibitor over 12 months especially in patients with stent implantation, the value of prolonged anticoagulation is still controversial. In the ATLAS-TIMI 52 trial, a low-dose direct factor Xa inhibition with rivaroxaban compared with placebo reduced the combined primary endpoint of cardiovascular mortality, myocardial infraction and stroke with an increase in major bleeding complications. This article discusses the value and problems of adding low-dose rivaroxaban to anti-platelet therapy as secondary prevention measure after an acute myocardial infarction. It will describe the pros and cons of intensified anti-platelet therapy versus dual pathway inhibition and give recommendations for different patient groups in clinical practice.",
keywords = "Acute Coronary Syndrome/drug therapy, Acute Disease, Anticoagulants/therapeutic use, Aspirin/therapeutic use, Clinical Trials as Topic, Drug Therapy, Combination, Factor Xa Inhibitors/therapeutic use, Humans, Myocardial Infarction/drug therapy, Practice Guidelines as Topic, Purinergic P2Y Receptor Antagonists/therapeutic use, Rivaroxaban/therapeutic use",
author = "Uwe Zeymer and Benedikt Schrage and Dirk Westermann",
note = "Georg Thieme Verlag KG Stuttgart · New York.",
year = "2018",
month = sep,
doi = "10.1055/s-0038-1668133",
language = "English",
volume = "118",
pages = "1528--1534",
journal = "THROMB HAEMOSTASIS",
issn = "0340-6245",
publisher = "Schattauer",
number = "9",

}

RIS

TY - JOUR

T1 - Dual Pathway Inhibition with Low-Dose Direct Factor Xa Inhibition after Acute Coronary Syndromes-Why Is It Not Used in Clinical Practice?

AU - Zeymer, Uwe

AU - Schrage, Benedikt

AU - Westermann, Dirk

N1 - Georg Thieme Verlag KG Stuttgart · New York.

PY - 2018/9

Y1 - 2018/9

N2 - The optimal anti-thrombotic therapy for secondary prevention after an acute coronary syndrome is still a matter of debate. While current guidelines recommend dual anti-platelet therapy with aspirin and a P2Y12 inhibitor over 12 months especially in patients with stent implantation, the value of prolonged anticoagulation is still controversial. In the ATLAS-TIMI 52 trial, a low-dose direct factor Xa inhibition with rivaroxaban compared with placebo reduced the combined primary endpoint of cardiovascular mortality, myocardial infraction and stroke with an increase in major bleeding complications. This article discusses the value and problems of adding low-dose rivaroxaban to anti-platelet therapy as secondary prevention measure after an acute myocardial infarction. It will describe the pros and cons of intensified anti-platelet therapy versus dual pathway inhibition and give recommendations for different patient groups in clinical practice.

AB - The optimal anti-thrombotic therapy for secondary prevention after an acute coronary syndrome is still a matter of debate. While current guidelines recommend dual anti-platelet therapy with aspirin and a P2Y12 inhibitor over 12 months especially in patients with stent implantation, the value of prolonged anticoagulation is still controversial. In the ATLAS-TIMI 52 trial, a low-dose direct factor Xa inhibition with rivaroxaban compared with placebo reduced the combined primary endpoint of cardiovascular mortality, myocardial infraction and stroke with an increase in major bleeding complications. This article discusses the value and problems of adding low-dose rivaroxaban to anti-platelet therapy as secondary prevention measure after an acute myocardial infarction. It will describe the pros and cons of intensified anti-platelet therapy versus dual pathway inhibition and give recommendations for different patient groups in clinical practice.

KW - Acute Coronary Syndrome/drug therapy

KW - Acute Disease

KW - Anticoagulants/therapeutic use

KW - Aspirin/therapeutic use

KW - Clinical Trials as Topic

KW - Drug Therapy, Combination

KW - Factor Xa Inhibitors/therapeutic use

KW - Humans

KW - Myocardial Infarction/drug therapy

KW - Practice Guidelines as Topic

KW - Purinergic P2Y Receptor Antagonists/therapeutic use

KW - Rivaroxaban/therapeutic use

U2 - 10.1055/s-0038-1668133

DO - 10.1055/s-0038-1668133

M3 - SCORING: Review article

C2 - 30103248

VL - 118

SP - 1528

EP - 1534

JO - THROMB HAEMOSTASIS

JF - THROMB HAEMOSTASIS

SN - 0340-6245

IS - 9

ER -